These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8834037)

  • 1. Interferon-induced "lupoid" thrombocytopenia in chronic hepatitis C.
    Tappero G; Guerrasio A; Gallo M; Negro F; Hadengue A; Angeli A
    J Hepatol; 1996 Jan; 24(1):124. PubMed ID: 8834037
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C.
    López Morante AJ; Sáez-Royuela F; Casanova Valero F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C
    Am J Gastroenterol; 1992 Jun; 87(6):809-10. PubMed ID: 1590332
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon-induced thrombocytopenia: is it time for thrombopoietin.
    Martin TG; Shuman MA
    Hepatology; 1998 Nov; 28(5):1430-2. PubMed ID: 9794932
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon treatment of cirrhotic patients with chronic hepatitis C.
    Andrade RJ; Lucena MI
    Am J Gastroenterol; 1995 Apr; 90(4):678-9. PubMed ID: 7536390
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab.
    Weitz IC
    Am J Hematol; 2005 Feb; 78(2):138-41. PubMed ID: 15682410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment.
    Toccaceli F; Rosati S; Scuderi M; Iacomi F; Picconi R; Laghi V
    Hepatogastroenterology; 1998; 45(23):1748-52. PubMed ID: 9840140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Case of C-type chronic hepatitis with manifestation of pituitary insufficiency caused by interferon therapy].
    Kato K; Arai K; Arai Y; Enomoto N; Yamada Y; Suzuki I; Tanaka M; Yoshihara H; Yamada Y; Abe H
    Nihon Naika Gakkai Zasshi; 1996 Oct; 85(10):1757-9. PubMed ID: 8999070
    [No Abstract]   [Full Text] [Related]  

  • 10. [Depression during interferon therapy in chronic hepatitis C patients--a prospective study].
    Otsubo T; Miyaoka H; Kamijima K; Onuki M; Ishii M; Mitamura K
    Seishin Shinkeigaku Zasshi; 1997; 99(3):101-27. PubMed ID: 9136611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of chronic hepatitis. Discussion].
    Nihon Naika Gakkai Zasshi; 1994 Feb; 83(2):269-85. PubMed ID: 7525803
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chronic hepatitis C. Predictive factors of response to treatment with interferon].
    López Alonso G
    An Med Interna; 1994 Dec; 11(12):573-4. PubMed ID: 7537545
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy of hepatitis C: overview.
    Lindsay KL
    Hepatology; 1997 Sep; 26(3 Suppl 1):71S-77S. PubMed ID: 9305668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia.
    Sohara N; Takagi H; Kakizaki S; Sato K; Mori M
    Transpl Int; 2006 Mar; 19(3):255-7. PubMed ID: 16441778
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.
    Poynard T; Leroy V; Cohard M; Thevenot T; Mathurin P; Opolon P; Zarski JP
    Hepatology; 1996 Oct; 24(4):778-89. PubMed ID: 8855176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe switch to beta-interferon treatment of chronic hepatitis C after alpha-interferon-induced autoimmune thrombocytopenia.
    Tappero G; Negro F; Farina M; Gallo M; Angeli A; Hadengue A
    J Hepatol; 1996 Aug; 25(2):270. PubMed ID: 8878792
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon and steroid treatment in patients with chronic hepatitis C and antinuclear or anti-liver-kidney microsomal antibodies.
    Provenzano G; Almasio P; Fabiano C; Magrin S; Pinzello G; Vaccaro A; Craxì A
    Ital J Gastroenterol; 1996 Sep; 28(7):377-80. PubMed ID: 8937938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
    Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy?
    Heathcote EJ
    Gastroenterology; 1995 Jun; 108(6):1942-4. PubMed ID: 7539390
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interferon therapy of hepatitis C].
    Furuta S; Kiyosawa K
    Nihon Naika Gakkai Zasshi; 1994 Feb; 83(2):230-4. PubMed ID: 7525799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.